Diverse immune evasion strategies by human cytomegalovirus

Immunologic Research

Volumn 54, Issue 1-3, 2012, Pages 140-151

  Noriega, Vanessa ^a   Redmann, Veronika ^a   Gardner, Thomas ^a   Tortorella, Domenico ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Degradation; Human cytomegalovirus; Immune evasion; Latency; Lytic infection; MHC antigen presentation; Proteasome; Unique short

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEASOME;

ANTIGEN PRESENTATION; ANTIVIRAL ACTIVITY; CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; LIFE CYCLE; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; STRESS; VIRUS CARRIER; VIRUS LATENCY; VIRUS REACTIVATION;

ANTIGEN PRESENTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNE EVASION; VIRUS LATENCY;

EID: 84867890628     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-012-8304-8     Document Type: Review

References (144)

1. Mocarski ES, Shenk T, Pass RF. Cytomegaloviruses. In: Howley DMKPM, editor. Fields virology. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007.
2. Slobedman B, Cao JZ, Avdic S, Webster B, McAllery S, Cheung AK, et al. Human cytomegalovirus latent infection and associated viral gene expression. Futur Microbiol. 2010;5(6):883-900. doi: 10.2217/fmb.10.58.
3. Sinclair J. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol. 2008;41(3):180-5. doi: 10.1016/j.jcv.2007.11.014.
4. Gibson W. Structure and formation of the cytomegalovirus virion. Curr Top Microbiol Immunol. 2008;325:187-204.
5. Compton T, Nowlin DM, Cooper NR. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology. 1993;193(2):834-41. doi: 10.1006/viro.1993.1192.
6. Isaacson MK, Juckem LK, Compton T. Virus entry and innate immune activation. Curr Top Microbiol Immunol. 2008;325:85-100.
7. Adler B, Scrivano L, Ruzcics Z, Rupp B, Sinzger C, Koszinowski U. Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol. 2006;87(Pt 9):2451-60. doi: 10.1099/vir.0.81921-0.
8. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol. 2004;78(18):10023-33. doi: 10.1128/JVI.78.18.10023-10033.2004.
9. Gerna G, Percivalle E, Lilleri D, Lozza L, Fornara C, Hahn G, et al. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol. 2005;86(Pt 2):275-84. doi: 10.1099/vir.0.80474-0.
10. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol. 2006;80(2):710-22. doi: 10.1128/JVI.80.2.710-722.2006.
11. Ryckman BJ, Rainish BL, Chase MC, Borton JA, Nelson JA, Jarvis MA, et al. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol. 2008;82(1):60-70. doi: 10.1128/JVI.01910-07.
12. Straschewski S, Patrone M, Walther P, Gallina A, Mertens T, Frascaroli G. Protein pUL128 of human cytomegalovirus is necessary for monocyte infection and blocking of migration. J Virol. 2011;85(10):5150-8. doi: 10.1128/JVI.02100-10.
13. Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA. 2005;102(50):18153-8. doi: 10.1073/pnas.0509201102.
14. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol. 1996;70(1):78-83.
15. Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L, Addison C, et al. Genetic content of wild-type human cytomegalovirus. J Gen Virol. 2004;85(Pt 5):1301-12.
16. Vanarsdall AL, Chase MC, Johnson DC. Human cytomegalovirus glycoprotein gO complexes with gH/gL, promoting interference with viral entry into human fibroblasts but not entry into epithelial cells. J Virol. 2011;85(22):11638-45. doi: 10.1128/JVI.05659-11.
17. Lopper M, Compton T. Coiled-coil domains in glycoproteins B and H are involved in human cytomegalovirus membrane fusion. J Virol. 2004;78(15):8333-41. doi: 10.1128/JVI.78.15.8333-8341.2004.
18. Ogawa-Goto K, Tanaka K, Gibson W, Moriishi E, Miura Y, Kurata T, et al. Microtubule network facilitates nuclear targeting of human cytomegalovirus capsid. J Virol. 2003;77(15):8541-7.
19. Cherrington JM, Mocarski ES. Human cytomegalovirus ie1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat element. J Virol. 1989;63(3):1435-40.
20. Meier JL, Stinski MF. Effect of a modulator deletion on transcription of the human cytomegalovirus major immediate-early genes in infected undifferentiated and differentiated cells. J Virol. 1997;71(2):1246-55.
21. Kalejta RF. Tegument proteins of human cytomegalovirus. Microbiol Mol Biol Rev. 2008;72(2):249-65. doi: 10.1128/MMBR.00040-07. table of contents.
22. Gant TM, Wilson KL. Nuclear assembly. Annu Rev Cell Dev Biol. 1997;13:669-95. doi: 10.1146/annurev.cellbio.13.1.669.
23. Radsak KD, Brucher KH, Georgatos SD. Focal nuclear envelope lesions and specific nuclear lamin A/C dephosphorylation during infection with human cytomegalovirus. Eur J Cell Biol. 1991;54(2):299-304.
24. Eickmann M, Gicklhorn D, Radsak K. Glycoprotein trafficking in virion morphogenesis. In: Reddehase M, Lemmermann N, editors. Cytomegaloviruses: molecular biology and immunology. Wymondham: Caister Academic Press; 2006. p. 245-64.
25. Sanchez V, Angeletti PC, Engler JA, Britt WJ. Localization of human cytomegalovirus structural proteins to the nuclear matrix of infected human fibroblasts. J Virol. 1998;72(4):3321-9.
26. Trus BL, Gibson W, Cheng N, Steven AC. Capsid structure of simian cytomegalovirus from cryoelectron microscopy: evidence for tegument attachment sites. J Virol. 1999;73(3):2181-92.
27. Liu W, Zhao Y, Biegalke B. Analysis of human cytomegalovirus US3 gene products. Virology. 2002;301(1):32-42.
28. Loewendorf A, Benedict CA. Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything. J Intern Med. 2010;267(5):483-501. doi: 10.1111/j.1365-2796.2010.02220.x.
29. Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. J Gen Virol. 2006;87(Pt 7):1763-79. doi: 10.1099/vir.0.81891-0.
30. Goodrum FD, Jordan CT, High K, Shenk T. Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. Proc Natl Acad Sci USA. 2002;99(25):16255-60. doi: 10.1073/pnas.252630899.
31. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci USA. 1998;95(7):3937-42.
32. Minton EJ, Tysoe C, Sinclair JH, Sissons JG. Human cytomegalovirus infection of the monocyte/macrophage lineage in bone marrow. J Virol. 1994;68(6):4017-21.
33. Reeves MB, MacAry PA, Lehner PJ, Sissons JG, Sinclair JH. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc Natl Acad Sci USA. 2005;102(11):4140-5. doi: 10.1073/pnas.0408994102.
34. Drew WL. Diagnosis of cytomegalovirus infection. Rev Infect Dis. 1988;10(Suppl 3):S468-76.
35. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis. 1990;12(Suppl 7):S754-66.
36. Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med. 2006;259(3):219-46. doi: 10.1111/j.1365-2796.2006.01618.x.
37. Adler SP. Transfusion-associated cytomegalovirus infections. Rev Infect Dis. 1983;5(6):977-93.
38. Tolpin MD, Stewart JA, Warren D, Mojica BA, Collins MA, Doveikis SA, et al. Transfusion transmission of cytomegalovirus confirmed by restriction endonuclease analysis. J Pediatr. 1985;107(6):953-6.
39. Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr. 1981;98(2):281-7.
40. Jordan MC. Latent infection and the elusive cytomegalovirus. Rev Infect Dis. 1983;5(2):205-15.
41. de Graan-Hentzen YC, Gratama JW, Mudde GC, Verdonck LF, Houbiers JG, Brand A, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion. 1989;29(9):757-60.
42. Stanier P, Taylor DL, Kitchen AD, Wales N, Tryhorn Y, Tyms AS. Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors. BMJ. 1989;299(6704):897-8.
43. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol. 1991;72(Pt 9):2059-64.
44. Mendelson M, Monard S, Sissons P, Sinclair J. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J Gen Virol. 1996;77(Pt 12):3099-102.
45. Slobedman B, Mocarski ES. Quantitative analysis of latent human cytomegalovirus. J Virol. 1999;73(6):4806-12.
46. Bolovan-Fritts CA, Mocarski ES, Wiedeman JA. Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood. 1999;93(1):394-8.
47. Jarvis MA, Fish KN, Soderberg-Naucler C, Streblow DN, Meyers HL, Thomas G, et al. Retrieval of human cytomegalovirus glycoprotein B from cell surface is not required for virus envelopment in astrocytoma cells. J Virol. 2002;76(10):5147-55.
48. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327(5963):291-5. doi: 327/5963/291.
49. Kumagai Y, Akira S. Identification and functions of pattern-recognition receptors. J Allergy Clin Immunol. 2010;125(5):985-92. doi: 10.1016/j.jaci.2010. 01.058.
50. Hirano M, Das S, Guo P, Cooper MD. The evolution of adaptive immunity in vertebrates. Adv Immunol. 2011;109:125-57. doi: 10.1016/B978-0-12-387664-5. 00004-2.
51. Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity. 2011;35(2):161-8. doi: 10.1016/j.immuni.2011.07.010.
52. Sheridan BS, Lefrancois L. Regional and mucosal memory T cells. Nat Immunol. 2011;12(6):485-91.
53. Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11(12):823-36. doi: 10.1038/nri3084.
54. Kushwah R, Hu J. Complexity of dendritic cell subsets and their function in the host immune system. Immunology. 2011;133(4):409-19. doi: 10.1111/j.1365-2567.2011.03457.x.
55. Nace G, Evankovich J, Eid R, Tsung A. Dendritic cells and damage-associated molecular patterns: endogenous danger signals linking innate and adaptive immunity. J Innate Immun. 2012;4(1):6-15. doi: 10.1159/000334245.
56. Rocha N, Neefjes J. MHC class II molecules on the move for successful antigen presentation. EMBO J. 2008;27(1):1-5. doi: 10.1038/sj.emboj.7601945.
57. Chapman DC, Williams DB. ER quality control in the biogenesis of MHC class I molecules. Semin Cell Dev Biol. 2010;21(5):512-9. doi: 10.1016/j.semcdb.2009.12.013.
58. Kurts C, Robinson BW, Knolle PA. Cross-priming in health and disease. Nat Rev Immunol. 2010;10(6):403-14. doi: 10.1038/nri2780.
59. Kracker S, Durandy A. Insights into the B cell specific process of immunoglobulin class switch recombination. Immunol Lett. 2011;138(2):97-103. doi: 10.1016/j.imlet.2011.02.004.
60. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. Annu Rev Immunol. 2000;18:861-926. doi: 10.1146/annurev.immunol.18.1.861.
61. Barnes PD, Grundy JE. Down-regulation of the class I HLA heterodimer and beta 2-microglobulin on the surface of cells infected with cytomegalovirus. J Gen Virol. 1992;73(Pt 9):2395-403.
62. Beersma MF, Bijlmakers MJ, Ploegh HL. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J Immunol. 1993;151(9):4455-64.
63. del Val M, Hengel H, Hacker H, Hartlaub U, Ruppert T, Lucin P, et al. Cytomegalovirus prevents antigen presentation by blocking the transport of peptide-loaded major histocompatibility complex class I molecules into the medial-Golgi compartment. J Exp Med. 1992;176(3):729-38.
64. Gilbert MJ, Riddell SR, Li CR, Greenberg PD. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol. 1993;67(6):3461-9.
65. Yamashita Y, Shimokata K, Mizuno S, Yamaguchi H, Nishiyama Y. Down-regulation of the surface expression of class I MHC antigens by human cytomegalovirus. Virology. 1993;193(2):727-36. doi: 10.1006/viro.1993.1181.
66. Jones TR, Hanson LK, Sun L, Slater JS, Stenberg RM, Campbell AE. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J Virol. 1995;69(8):4830-41.
67. Ahn K, Angulo A, Ghazal P, Peterson PA, Yang Y, Fruh K. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci USA. 1996;93(20):10990-5.
68. Jones TR, Wiertz EJ, Sun L, Fish KN, Nelson JA, Ploegh HL. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci USA. 1996;93(21):11327-33.
69. Lee S, Park B, Ahn K. Determinant for endoplasmic reticulum retention in the luminal domain of the human cytomegalovirus US3 glycoprotein. J Virol. 2003;77(3):2147-56.
70. Zhao Y, Biegalke BJ. Functional analysis of the human cytomegalovirus immune evasion protein, pUS3 (22 kDa). Virology. 2003;315(2):353-61.
71. Park B, Kim Y, Shin J, Lee S, Cho K, Fruh K, et al. Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity. 2004;20(1):71-85.
72. Jun Y, Kim E, Jin M, Sung HC, Han H, Geraghty DE, et al. Human cytomegalovirus gene products US3 and US6 down-regulate trophoblast class I MHC molecules. J Immunol. 2000;164(2):805-11.
73. Noriega VM, Tortorella D. Human cytomegalovirus-encoded immune modulators partner to downregulate major histocompatibility complex class I molecules. J Virol. 2009;83(3):1359-67. doi: 10.1128/JVI.01324-08.
74. Hegde NR, Tomazin RA, Wisner TW, Dunn C, Boname JM, Lewinsohn DM, et al. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation. J Virol. 2002;76(21):10929-41.
75. Jones TR, Sun L. Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. J Virol. 1997;71(4):2970-9.
76. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell. 1996;84(5):769-79.
77. Wiertz EJ, Tortorella D, Bogyo M, Yu J, Mothes W, Jones TR, et al. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature. 1996;384(6608):432-8. doi: 10.1038/384432a0.
78. Smith MH, Ploegh HL, Weissman JS. Road to ruin: targeting proteins for degradation in the endoplasmic reticulum. Science. 2011;334(6059):1086-90. doi: 10.1126/science.1209235.
79. Lilley BN, Tortorella D, Ploegh HL. Dislocation of a type I membrane protein requires interactions between membrane-spanning segments within the lipid bilayer. Mol Biol Cell. 2003;14(9):3690-8. doi: 10.1091/mbc.E03-03-0192.
80. Noriega VM, Tortorella D. A bipartite trigger for dislocation directs the proteasomal degradation of an endoplasmic reticulum membrane glycoprotein. J Biol Chem. 2008;283(7):4031-43. doi: 10.1074/jbc.M706283200.
81. Oresic K, Noriega V, Andrews L, Tortorella D. A structural determinant of human cytomegalovirus US2 dictates the down-regulation of class I major histocompatibility molecules. J Biol Chem. 2006;281(28):19395-406. doi: 10.1074/jbc.M601026200.
82. Rehm A, Engelsberg A, Tortorella D, Korner IJ, Lehmann I, Ploegh HL, et al. Human cytomegalovirus gene products US2 and US11 differ in their ability to attack major histocompatibility class I heavy chains in dendritic cells. J Virol. 2002;76(10):5043-50.
83. Tomazin R, Boname J, Hegde NR, Lewinsohn DM, Altschuler Y, Jones TR, et al. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat Med. 1999;5(9):1039-43. doi: 10.1038/12478.
84. Barel MT, Ressing M, Pizzato N, van Leeuwen D, Le Bouteiller P, Lenfant F, et al. Human cytomegalovirus-encoded US2 differentially affects surface expression of MHC class I locus products and targets membrane-bound, but not soluble HLA-G1 for degradation. J Immunol. 2003;171(12):6757-65.
85. Gewurz BE, Wang EW, Tortorella D, Schust DJ, Ploegh HL. Human cytomegalovirus US2 endoplasmic reticulum-lumenal domain dictates association with major histocompatibility complex class I in a locus-specific manner. J Virol. 2001;75(11):5197-204. doi: 10.1128/JVI.75.11.5197-5204.2001.
86. Barel MT, Pizzato N, van Leeuwen D, Bouteiller PL, Wiertz EJ, Lenfant F. Amino acid composition of alpha1/alpha2 domains and cytoplasmic tail of MHC class I molecules determine their susceptibility to human cytomegalovirus US11-mediated down-regulation. Eur J Immunol. 2003;33(6):1707-16. doi: 10.1002/eji.200323912.
87. Oresic K, Tortorella D. Endoplasmic reticulum chaperones participate in human cytomegalovirus US2-mediated degradation of class I major histocompatibility complex molecules. J Gen Virol. 2008;89(Pt 5):1122-30. doi: 10.1099/vir.0.83516-0.
88. Gewurz BE, Gaudet R, Tortorella D, Wang EW, Ploegh HL, Wiley DC. Antigen presentation subverted: structure of the human cytomegalovirus protein US2 bound to the class I molecule HLA-A2. Proc Natl Acad Sci USA. 2001;98(12):6794-9. doi: 10.1073/pnas.121172898.
89. Story CM, Furman MH, Ploegh HL. The cytosolic tail of class I MHC heavy chain is required for its dislocation by the human cytomegalovirus US2 and US11 gene products. Proc Natl Acad Sci USA. 1999;96(15):8516-21.
90. Schust DJ, Tortorella D, Seebach J, Phan C, Ploegh HL. Trophoblast class I major histocompatibility complex (MHC) products are resistant to rapid degradation imposed by the human cytomegalovirus (HCMV) gene products US2 and US11. J Exp Med. 1998;188(3):497-503.
91. Besold K, Frankenberg N, Pepperl-Klindworth S, Kuball J, Theobald M, Hahn G, et al. Processing and MHC class I presentation of human cytomegalovirus pp 65-derived peptides persist despite gpUS2-11-mediated immune evasion. J Gen Virol. 2007;88(Pt 5):1429-39. doi: 10.1099/vir.0.82686-0.
92. Besold K, Wills M, Plachter B. Immune evasion proteins gpUS2 and gpUS11 of human cytomegalovirus incompletely protect infected cells from CD8 T cell recognition. Virology. 2009;391(1):5-19. doi: 10.1016/j.virol.2009.06.004.
93. Vembar SS, Brodsky JL. One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol. 2008;9(12):944-57. doi: 10.1038/nrm2546.
94. Hegde NR, Chevalier MS, Wisner TW, Denton MC, Shire K, Frappier L, et al. The role of BiP in endoplasmic reticulum-associated degradation of major histocompatibility complex class I heavy chain induced by cytomegalovirus proteins. J Biol Chem. 2006;281(30):20910-9. doi: 10.1074/jbc.M602989200.
95. Lilley BN, Ploegh HL. A membrane protein required for dislocation of misfolded proteins from the ER. Nature. 2004;429(6994):834-40. doi: 10.1038/nature02592.
96. Mueller B, Klemm EJ, Spooner E, Claessen JH, Ploegh HL. SEL1L nucleates a protein complex required for dislocation of misfolded glycoproteins. Proc Natl Acad Sci USA. 2008;105(34):12325-30. doi: 10.1073/pnas.0805371105.
97. Mueller B, Lilley BN, Ploegh HL. SEL1L, the homologue of yeast Hrd3p, is involved in protein dislocation from the mammalian ER. J Cell Biol. 2006;175(2):261-70. doi: 10.1083/jcb.200605196.
98. Ye Y, Meyer HH, Rapoport TA. The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature. 2001;414(6864):652-6. doi: 10.1038/414652a.
99. Ye Y, Shibata Y, Yun C, Ron D, Rapoport TA. A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol. Nature. 2004;429(6994):841-7. doi: 10.1038/nature02656.
100. Loureiro J, Lilley BN, Spooner E, Noriega V, Tortorella D, Ploegh HL. Signal peptide peptidase is required for dislocation from the endoplasmic reticulum. Nature. 2006;441(7095):894-7. doi: 10.1038/nature04830.
101. Soetandyo N, Ye Y. The p97 ATPase dislocates MHC class I heavy chain in US2-expressing cells via a Ufd1-Npl4-independent mechanism. J Biol Chem. 2010;285(42):32352-9. doi: 10.1074/jbc.M110.131649.
102. Furman MH, Dey N, Tortorella D, Ploegh HL. The human cytomegalovirus US10 gene product delays trafficking of major histocompatibility complex class I molecules. J Virol. 2002;76(22):11753-6.
103. Park B, Spooner E, Houser BL, Strominger JL, Ploegh HL. The HCMV membrane glycoprotein US10 selectively targets HLA-G for degradation. J Exp Med. 2010;207(9):2033-41. doi: 10.1084/jem.20091793.
104. Lehner PJ, Karttunen JT, Wilkinson GW, Cresswell P. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc Natl Acad Sci USA. 1997;94(13):6904-9.
105. Ahn K, Gruhler A, Galocha B, Jones TR, Wiertz EJ, Ploegh HL, et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity. 1997;6(5):613-21.
106. Dugan GE, Hewitt EW. Structural and functional dissection of the human cytomegalovirus immune evasion protein US6. J Virol. 2008;82(7):3271-82. doi: 10.1128/JVI.01705-07.
107. Hewitt EW, Gupta SS, Lehner PJ. The human cytomegalovirus gene product US6 inhibits ATP binding by TAP. EMBO J. 2001;20(3):387-96. doi: 10.1093/emboj/20.3.387.
108. Kyritsis C, Gorbulev S, Hutschenreiter S, Pawlitschko K, Abele R, Tampe R. Molecular mechanism and structural aspects of transporter associated with antigen processing inhibition by the cytomegalovirus protein US6. J Biol Chem. 2001;276(51):48031-9. doi: 10.1074/jbc.M108528200.
109. Kim Y, Park B, Cho S, Shin J, Cho K, Jun Y, et al. Human cytomegalovirus UL18 utilizes US6 for evading the NK and T-cell responses. PLoS Pathog. 2008;4(8):e1000123. doi: 10.1371/journal.ppat.1000123.
110. Park B, Oh H, Lee S, Song Y, Shin J, Sung YC, et al. The MHC class I homolog of human cytomegalovirus is resistant to down-regulation mediated by the unique short region protein (US)2, US3, US6, and US11 gene products. J Immunol. 2002;168(7):3464-9.
111. Kim S, Lee S, Shin J, Kim Y, Evnouchidou I, Kim D, et al. Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1. Nat Immunol. 2011;12(10):984-91. doi: 10.1038/ni.2097.
112. Saric T, Chang SC, Hattori A, York IA, Markant S, Rock KL, et al. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol. 2002;3(12):1169-76. doi: 10.1038/ni859.
113. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature. 1996;383(6602):720-2. doi: 10.1038/383720a0.
114. Trgovcich J, Cebulla C, Zimmerman P, Sedmak DD. Human cytomegalovirus protein pp 71 disrupts major histocompatibility complex class I cell surface expression. J Virol. 2006;80(2):951-63. doi: 10.1128/JVI.80.2.951-963.2006.
115. Gallina A, Simoncini L, Garbelli S, Percivalle E, Pedrali-Noy G, Lee KS, et al. Polo-like kinase 1 as a target for human cytomegalovirus pp 65 lower matrix protein. J Virol. 1999;73(2):1468-78.
116. Browne EP, Shenk T. Human cytomegalovirus UL83-coded pp 65 virion protein inhibits antiviral gene expression in infected cells. Proc Natl Acad Sci USA. 2003;100(20):11439-44. doi: 10.1073/pnas.1534570100.
117. Odeberg J, Plachter B, Branden L, Soderberg-Naucler C. Human cytomegalovirus protein pp 65 mediates accumulation of HLA-DR in lysosomes and destruction of the HLA-DR alpha-chain. Blood. 2003;101(12):4870-7. doi: 10.1182/blood-2002-05-1504.
118. Khan N, Bruton R, Taylor GS, Cobbold M, Jones TR, Rickinson AB, et al. Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes. J Virol. 2005;79(5):2869-79. doi: 10.1128/JVI.79.5.2869-2879.2005.
119. Hansen SG, Powers CJ, Richards R, Ventura AB, Ford JC, Siess D, et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science. 2010;328(5974):102-6. doi: 10.1126/science.1185350.
120. Lemmermann NA, Bohm V, Holtappels R, Reddehase MJ. In vivo impact of cytomegalovirus evasion of CD8 T-cell immunity: facts and thoughts based on murine models. Virus Res. 2011;157(2):161-74. doi: 10.1016/j.virusres.2010.09. 022.
121. Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature. 1988;331(6153):269-72. doi: 10.1038/331269a0.
122. Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity. 1997;7(2):273-82.
123. Kubin M, Cassiano L, Chalupny J, Chin W, Cosman D, Fanslow W, et al. ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol. 2001;31(5):1428-37. doi: 10.1002/1521-4141(200105)31:5<1428:AID- IMMU1428>3.0.CO;2-4.
124. Welte SA, Sinzger C, Lutz SZ, Singh-Jasuja H, Sampaio KL, Eknigk U, et al. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol. 2003;33(1):194-203. doi: 10.1002/immu.200390022.
125. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med. 1998;187(5):813-8.
126. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391(6669):795-9. doi: 10.1038/35869.
127. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA. 1998;95(9):5199-204.
128. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5):495-502. doi: 10.1038/ni1581.
129. Orange JS, Fassett MS, Koopman LA, Boyson JE, Strominger JL. Viral evasion of natural killer cells. Nat Immunol. 2002;3(11):1006-12. doi: 10.1038/ni1102-1006.
130. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R, et al. Modulation of natural killer cells by human cytomegalovirus. J Clin Virol. 2008;41(3):206-12. doi: 10.1016/j.jcv.2007.10.027.
131. Chang WL, Baumgarth N, Yu D, Barry PA. Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality. J Virol. 2004;78(16):8720-31. doi: 10.1128/JVI.78.16.8720-8731. 2004.
132. Jenkins C, Abendroth A, Slobedman B. A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection. J Virol. 2004;78(3):1440-7.
133. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci USA. 2000;97(4):1695-700.
134. Raftery MJ, Wieland D, Gronewald S, Kraus AA, Giese T, Schonrich G. Shaping phenotype, function, and survival of dendritic cells by cytomegalovirus-encoded IL-10. J Immunol. 2004;173(5):3383-91.
135. Spencer JV, Lockridge KM, Barry PA, Lin G, Tsang M, Penfold ME, et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol. 2002;76(3):1285-92.
136. Slobedman B, Mocarski ES, Arvin AM, Mellins ED, Abendroth A. Latent cytomegalovirus down-regulates major histocompatibility complex class II expression on myeloid progenitors. Blood. 2002;100(8):2867-73. doi: 10.1182/blood.V100.8.2867.
137. Cheung AK, Gottlieb DJ, Plachter B, Pepperl-Klindworth S, Avdic S, Cunningham AL, et al. The role of the human cytomegalovirus UL111A gene in down-regulating CD4+ T-cell recognition of latently infected cells: implications for virus elimination during latency. Blood. 2009;114(19):4128-37. doi: 10.1182/blood-2008-12-197111.
138. Gredmark S, Soderberg-Naucler C. Human cytomegalovirus inhibits differentiation of monocytes into dendritic cells with the consequence of depressed immunological functions. J Virol. 2003;77(20):10943-56.
139. Rolle A, Olweus J. Dendritic cells in cytomegalovirus infection: viral evasion and host countermeasures. APMIS. 2009;117(5-6):413-26. doi: 10.1111/j.1600-0463.2009.02449.x.
140. Carlier J, Martin H, Mariame B, Rauwel B, Mengelle C, Weclawiak H, et al. Paracrine inhibition of GM-CSF signaling by human cytomegalovirus in monocytes differentiating to dendritic cells. Blood. 2011;118(26):6783-92. doi: 10.1182/blood-2011-02-337956.
141. Frascaroli G, Varani S, Mastroianni A, Britton S, Gibellini D, Rossini G, et al. Dendritic cell function in cytomegalovirus-infected patients with mononucleosis. J Leukoc Biol. 2006;79(5):932-40. doi: 10.1189/jlb.0905499.
142. Kvale EO, Dalgaard J, Lund-Johansen F, Rollag H, Farkas L, Midtvedt K, et al. CD11c+ dendritic cells and plasmacytoid DCs are activated by human cytomegalovirus and retain efficient T cell-stimulatory capability upon infection. Blood. 2006;107(5):2022-9. doi: 10.1182/blood-2005-05-2016.
143. Reeves MB, Compton T. Inhibition of inflammatory interleukin-6 activity via extracellular signal-regulated kinase-mitogen-activated protein kinase signaling antagonizes human cytomegalovirus reactivation from dendritic cells. J Virol. 2011;85(23):12750-8. doi: 10.1128/JVI.05878-11.
144. Shamu CE, Flierman D, Ploegh HL, Rapoport TA, Chau V. Polyubiquitination is required for US11-dependent movement of MHC class I heavy chain from endoplasmic reticulum into cytosol. Mol Biol Cell. 2001;12(8):2546-55.